WO2006074891A3 - Proteines contenant des lymphocytes t regulateurs et destinees au traitement et au diagnostic de maladies - Google Patents

Proteines contenant des lymphocytes t regulateurs et destinees au traitement et au diagnostic de maladies Download PDF

Info

Publication number
WO2006074891A3
WO2006074891A3 PCT/EP2006/000122 EP2006000122W WO2006074891A3 WO 2006074891 A3 WO2006074891 A3 WO 2006074891A3 EP 2006000122 W EP2006000122 W EP 2006000122W WO 2006074891 A3 WO2006074891 A3 WO 2006074891A3
Authority
WO
WIPO (PCT)
Prior art keywords
illnesses
diagnosis
therapy
proteins containing
cells
Prior art date
Application number
PCT/EP2006/000122
Other languages
German (de)
English (en)
Other versions
WO2006074891A2 (fr
Inventor
Petra Lutter
Helmut Jonuleit
Petra Weingarten
Edgar Schmitt
Helmut E Meyer
Original Assignee
Protagen Ag
Petra Lutter
Helmut Jonuleit
Petra Weingarten
Edgar Schmitt
Helmut E Meyer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protagen Ag, Petra Lutter, Helmut Jonuleit, Petra Weingarten, Edgar Schmitt, Helmut E Meyer filed Critical Protagen Ag
Publication of WO2006074891A2 publication Critical patent/WO2006074891A2/fr
Publication of WO2006074891A3 publication Critical patent/WO2006074891A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464839—Allergens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Rehabilitation Therapy (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne de nouvelles protéines contenant des lymphocytes T régulateurs correspondant à la séquence d'acide aminé (voir SEQ ID No. 1-27) comme telle, notamment leur utilisation comme marqueurs ainsi que et pour le traitement et le diagnostic de maladies, notamment d'allergies, de maladies auto-immunes, notamment l'arthrite rhumatoïde, la sclérose en plaques ou la maladie de Crohn, l'inflammation chronique, l'asthme, les maladies d'immuno-déficience, le sida les rejets de greffes et les maladies cancéreuses comme le diabète.
PCT/EP2006/000122 2005-01-17 2006-01-10 Proteines contenant des lymphocytes t regulateurs et destinees au traitement et au diagnostic de maladies WO2006074891A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005002110A DE102005002110A1 (de) 2005-01-17 2005-01-17 Regulatorische-T-Zellen enthaltend Proteine zur Therapie und Diagnose von Erkrankungen
DE102005002110.7 2005-01-17

Publications (2)

Publication Number Publication Date
WO2006074891A2 WO2006074891A2 (fr) 2006-07-20
WO2006074891A3 true WO2006074891A3 (fr) 2007-01-04

Family

ID=36127913

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/000122 WO2006074891A2 (fr) 2005-01-17 2006-01-10 Proteines contenant des lymphocytes t regulateurs et destinees au traitement et au diagnostic de maladies

Country Status (2)

Country Link
DE (1) DE102005002110A1 (fr)
WO (1) WO2006074891A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007041657A1 (de) * 2007-09-03 2009-03-05 Protagen Ag Markersequenzen für Multiple Sklerose und deren Verwendung

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003008558A2 (fr) * 2001-07-20 2003-01-30 University Of Iowa Research Foundation Clones d'hybridomes inhibiteurs cd4?+cd25+¿
WO2003077872A2 (fr) * 2002-03-15 2003-09-25 Attenuon, Llc Tropomyosine de surface cellulaire servant de cible de l'inhibition de l'angiogenese
WO2005007836A1 (fr) * 2003-07-15 2005-01-27 Protagen Ag Lymphocytes t regulateurs contenant de la galectine pour le traitement et le diagnostic de maladies
WO2005070090A2 (fr) * 2004-01-08 2005-08-04 Regents Of The University Of California Lymphocytes t regulateurs supprimant l'auto-immunite

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1241249A1 (fr) * 2001-03-12 2002-09-18 Gerold Schuler Lymphocytes T CD4+CD25+ régulateurs provenant du sang humain

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003008558A2 (fr) * 2001-07-20 2003-01-30 University Of Iowa Research Foundation Clones d'hybridomes inhibiteurs cd4?+cd25+¿
WO2003077872A2 (fr) * 2002-03-15 2003-09-25 Attenuon, Llc Tropomyosine de surface cellulaire servant de cible de l'inhibition de l'angiogenese
WO2005007836A1 (fr) * 2003-07-15 2005-01-27 Protagen Ag Lymphocytes t regulateurs contenant de la galectine pour le traitement et le diagnostic de maladies
WO2005070090A2 (fr) * 2004-01-08 2005-08-04 Regents Of The University Of California Lymphocytes t regulateurs supprimant l'auto-immunite

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JONULEIT H ET AL: "The regulatory T cell family : Distinct subsets and their interrelations", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 171, December 2003 (2003-12-01), pages 6323 - 6327, XP002270348, ISSN: 0022-1767 *
LUTTER P ET AL: "Proteome analysis of regulatory T cells: Promising targets for innovative immunotherapeutical approaches.", MOLECULAR & CELLULAR PROTEOMICS, vol. 2, no. 9, September 2003 (2003-09-01), & HUPO (HUMAN PROTEOMICS ORGANISATION) 2ND ANNUAL AND IUBMB (INTERNATIONAL UNION OF BIOCHEMISTRY AND M; MONTREAL, QUEBEC, CANADA; OCTOBER 08-11, 2003, pages 990, XP002377180, ISSN: 1535-9476 *
STASSEN MICHAEL ET AL: "Human CD25+ regulatory T cells: two subsets defined by the integrins alpha4beta7 or alpha4beta1 confer distinct suppressive properties upon CD4+ T helper cells", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 34, no. 5, May 2004 (2004-05-01), pages 1303 - 1311, XP002377231, ISSN: 0014-2980 *

Also Published As

Publication number Publication date
WO2006074891A2 (fr) 2006-07-20
DE102005002110A1 (de) 2006-07-27

Similar Documents

Publication Publication Date Title
WO2006119170A3 (fr) Utilisation de peptides derives de cytokine pour traiter la douleur et une maladie neurodegenerative
IL129299A0 (en) Monoclonal antibodies antigens and diagnosis of malignant diseases
WO2005019258A3 (fr) Compositions et methodes de traitement de maladies relatives au systeme immunitaire
WO2007149542A3 (fr) Compositions de chémokine microbicide antimicrobiennes et procédés d'utilisation
NZ621196A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
WO2005103712A3 (fr) Utilisation de precurseurs de tachykinines et/ou de fragments de celles-ci dans un diagnostic medical
WO2008106980A3 (fr) Anticorps recombinants pour le traitement des infections au virus respiratoire syncytial
WO2007147019A3 (fr) Antagonistes d'il-17 et d'il-23 et leurs procédés d'utilisation
EP2527369A3 (fr) Anticorps monoclonal anti-bêta-amyloide (abêta) et ses utilisations
WO2004078777A3 (fr) Proteines protegees contre la dipeptidylpeptidase
ATA14642003A (de) Impfstoff für die alzheimer-krankheit
NO330984B1 (no) Aminosyre-fenoksyestere, fremgangsmate for fremstilling av slike, mellomprodukter i synteseveien, farmasoytisk preparat omfattende slike samt anvendelse av slike for fremstilling av farmasoytisk preparat for behandling av sykdom
JP2006506942A5 (fr)
WO2006138745A3 (fr) Peptides et vaccins therapeutiques
WO2006028561A3 (fr) Nouveaux polypeptides fabi purifies issus de fransicella tularensis
WO2006137938A3 (fr) Fragments d'anticorps assurant la protection contre l'infection par des pathogenes, methodes d'utilisation de ces derniers
WO2007093848A3 (fr) Nouveaux polypeptides purifiés issus de helicobacter pylori
WO2004024072A3 (fr) Nouvelles compositions et methodes pour le traitement de maladies associees au systeme immunitaire
WO2006074891A3 (fr) Proteines contenant des lymphocytes t regulateurs et destinees au traitement et au diagnostic de maladies
WO2006016172A3 (fr) Glycoproteine de surface
WO2007066018A3 (fr) Peptides qui peuvent se lier a la proteine nef et leurs applications pharmaceutiques
WO2006043060A3 (fr) Proteine contenant le domaine mam
WO2006010805A3 (fr) Nouveaux polypeptides pour la mise en evidence in vitro et la prevention des infections a legionella pneumophila
WO2009083968A8 (fr) Nouvelle protéine
WO2004043397A3 (fr) Compositions et procedes pour le traitement de la polyarthrite rhumatoide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06700003

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6700003

Country of ref document: EP